Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by CCAbbott888on Apr 25, 2019 7:36pm
157 Views
Post# 29672317

RE:RE:WHY INSIDER NOT BUYING?

RE:RE:WHY INSIDER NOT BUYING?
Trappers wrote:
Insiders don't need to buy ever again. They just stole the whole company, and our life savings. All we can do is keep voicing our outrage to the authorities and politicians.
Trappers  You should do both.  Do all you can in filing your complaints, but also consider how you can get out of this bad situation with least amount of loss, in case the security authority do not intervene.

As I told others, if you really don't want to put in new money, then sell some now to raise the money for the rights offer of your remaining shares, it may not go very far in lowering your average, but it's better than if you do not take part in the rights offer at all.

If the big funds are closing their positons as charm7 posted earlier, then retailers may have a chance to get their subscibed amount filled closer to 20 than 6.7, which should help lowering the average cost considerably.  

The risk, of course, is further bad news, instead of good news by 2H 2019.  However, it's a potential risk (meaning it may not happen) vs. the refinancing plan that has already happened.
All the best, Trappers.
Bullboard Posts